Autoimmune targets of heart and skeletal muscles in myasthenia gravis

Shigeaki Suzuki, Kimiaki Utsugisawa, Hiroaki Yoshikawa, Masakatsu Motomura, Shiro Matsubara, Kazumasa Yokoyama, Yuriko Nagane, Takahiro Maruta, Takashi Satoh, Hideki Sato, Masataka Kuwana, Norihiro Suzuki

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: To investigate the clinical, histological, and immunological features of patients with myasthenia gravis (MG) who also developed myocarditis and/or myositis. Design: Observational and retrospective case series. Setting: Keio University, Hanamaki General Hospital, Kanazawa University, Nagasaki University, and Juntendo University. Patients: A cohort of 8 patients with MG with clinically defined inflammatory myopathies. Interventions: Clinical and histological features were described. Serological analyses included MG-related antistriational autoantibodies (those to titin, ryanodine receptor, muscular voltage-gated potassium channel Kv1.4) and myositis-specific autoantibodies. Results: Of 924 patients with MG, 8 (0.9%) had inflammatory myopathies. The mean (SD) onset age ofMGwas 55.3(10.3) years. All patients showed severe symptoms with bulbar involvement; 5 patients had myasthenic crisis and 4 had invasive thymoma. Myocarditis was found in 3 patients and myositis in 6. Myocarditis, developing 13 to 211 months after the MG onset, was characterized by heart failure and arrhythmias. Myositis, developing before or at the same time as MG, affected limb and paraspinal muscles. Histological findings of skeletal muscles showed CD8+ lymphocyte infiltration. Seven patients had 1 of these antistriational autoantibodies but not myositis-specific autoantibodies. Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died. Conclusions: Heart and skeletal muscles are autoimmune targets in some patients with MG. This autoimmunity has a broad clinical spectrum with antistriational autoantibodies.

Original languageEnglish
Pages (from-to)1334-1338
Number of pages5
JournalArchives of Neurology
Volume66
Issue number11
DOIs
Publication statusPublished - 2009 Nov

Fingerprint

Myasthenia Gravis
Myositis
Myocardium
Skeletal Muscle
Autoantibodies
Myocarditis
Connectin
Paraspinal Muscles
Voltage-Gated Potassium Channels
Ryanodine Receptor Calcium Release Channel
Thymoma
Immunomodulation
Muscle Weakness
Autoimmunity
Age of Onset
General Hospitals
Cardiac Arrhythmias
Extremities
Heart Failure
Lymphocytes

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Suzuki, S., Utsugisawa, K., Yoshikawa, H., Motomura, M., Matsubara, S., Yokoyama, K., ... Suzuki, N. (2009). Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Archives of Neurology, 66(11), 1334-1338. https://doi.org/10.1001/archneurol.2009.229

Autoimmune targets of heart and skeletal muscles in myasthenia gravis. / Suzuki, Shigeaki; Utsugisawa, Kimiaki; Yoshikawa, Hiroaki; Motomura, Masakatsu; Matsubara, Shiro; Yokoyama, Kazumasa; Nagane, Yuriko; Maruta, Takahiro; Satoh, Takashi; Sato, Hideki; Kuwana, Masataka; Suzuki, Norihiro.

In: Archives of Neurology, Vol. 66, No. 11, 11.2009, p. 1334-1338.

Research output: Contribution to journalArticle

Suzuki, S, Utsugisawa, K, Yoshikawa, H, Motomura, M, Matsubara, S, Yokoyama, K, Nagane, Y, Maruta, T, Satoh, T, Sato, H, Kuwana, M & Suzuki, N 2009, 'Autoimmune targets of heart and skeletal muscles in myasthenia gravis', Archives of Neurology, vol. 66, no. 11, pp. 1334-1338. https://doi.org/10.1001/archneurol.2009.229
Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Archives of Neurology. 2009 Nov;66(11):1334-1338. https://doi.org/10.1001/archneurol.2009.229
Suzuki, Shigeaki ; Utsugisawa, Kimiaki ; Yoshikawa, Hiroaki ; Motomura, Masakatsu ; Matsubara, Shiro ; Yokoyama, Kazumasa ; Nagane, Yuriko ; Maruta, Takahiro ; Satoh, Takashi ; Sato, Hideki ; Kuwana, Masataka ; Suzuki, Norihiro. / Autoimmune targets of heart and skeletal muscles in myasthenia gravis. In: Archives of Neurology. 2009 ; Vol. 66, No. 11. pp. 1334-1338.
@article{f1f07ade7f9e4a779c7e9154f6547a6d,
title = "Autoimmune targets of heart and skeletal muscles in myasthenia gravis",
abstract = "Objective: To investigate the clinical, histological, and immunological features of patients with myasthenia gravis (MG) who also developed myocarditis and/or myositis. Design: Observational and retrospective case series. Setting: Keio University, Hanamaki General Hospital, Kanazawa University, Nagasaki University, and Juntendo University. Patients: A cohort of 8 patients with MG with clinically defined inflammatory myopathies. Interventions: Clinical and histological features were described. Serological analyses included MG-related antistriational autoantibodies (those to titin, ryanodine receptor, muscular voltage-gated potassium channel Kv1.4) and myositis-specific autoantibodies. Results: Of 924 patients with MG, 8 (0.9{\%}) had inflammatory myopathies. The mean (SD) onset age ofMGwas 55.3(10.3) years. All patients showed severe symptoms with bulbar involvement; 5 patients had myasthenic crisis and 4 had invasive thymoma. Myocarditis was found in 3 patients and myositis in 6. Myocarditis, developing 13 to 211 months after the MG onset, was characterized by heart failure and arrhythmias. Myositis, developing before or at the same time as MG, affected limb and paraspinal muscles. Histological findings of skeletal muscles showed CD8+ lymphocyte infiltration. Seven patients had 1 of these antistriational autoantibodies but not myositis-specific autoantibodies. Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died. Conclusions: Heart and skeletal muscles are autoimmune targets in some patients with MG. This autoimmunity has a broad clinical spectrum with antistriational autoantibodies.",
author = "Shigeaki Suzuki and Kimiaki Utsugisawa and Hiroaki Yoshikawa and Masakatsu Motomura and Shiro Matsubara and Kazumasa Yokoyama and Yuriko Nagane and Takahiro Maruta and Takashi Satoh and Hideki Sato and Masataka Kuwana and Norihiro Suzuki",
year = "2009",
month = "11",
doi = "10.1001/archneurol.2009.229",
language = "English",
volume = "66",
pages = "1334--1338",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Autoimmune targets of heart and skeletal muscles in myasthenia gravis

AU - Suzuki, Shigeaki

AU - Utsugisawa, Kimiaki

AU - Yoshikawa, Hiroaki

AU - Motomura, Masakatsu

AU - Matsubara, Shiro

AU - Yokoyama, Kazumasa

AU - Nagane, Yuriko

AU - Maruta, Takahiro

AU - Satoh, Takashi

AU - Sato, Hideki

AU - Kuwana, Masataka

AU - Suzuki, Norihiro

PY - 2009/11

Y1 - 2009/11

N2 - Objective: To investigate the clinical, histological, and immunological features of patients with myasthenia gravis (MG) who also developed myocarditis and/or myositis. Design: Observational and retrospective case series. Setting: Keio University, Hanamaki General Hospital, Kanazawa University, Nagasaki University, and Juntendo University. Patients: A cohort of 8 patients with MG with clinically defined inflammatory myopathies. Interventions: Clinical and histological features were described. Serological analyses included MG-related antistriational autoantibodies (those to titin, ryanodine receptor, muscular voltage-gated potassium channel Kv1.4) and myositis-specific autoantibodies. Results: Of 924 patients with MG, 8 (0.9%) had inflammatory myopathies. The mean (SD) onset age ofMGwas 55.3(10.3) years. All patients showed severe symptoms with bulbar involvement; 5 patients had myasthenic crisis and 4 had invasive thymoma. Myocarditis was found in 3 patients and myositis in 6. Myocarditis, developing 13 to 211 months after the MG onset, was characterized by heart failure and arrhythmias. Myositis, developing before or at the same time as MG, affected limb and paraspinal muscles. Histological findings of skeletal muscles showed CD8+ lymphocyte infiltration. Seven patients had 1 of these antistriational autoantibodies but not myositis-specific autoantibodies. Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died. Conclusions: Heart and skeletal muscles are autoimmune targets in some patients with MG. This autoimmunity has a broad clinical spectrum with antistriational autoantibodies.

AB - Objective: To investigate the clinical, histological, and immunological features of patients with myasthenia gravis (MG) who also developed myocarditis and/or myositis. Design: Observational and retrospective case series. Setting: Keio University, Hanamaki General Hospital, Kanazawa University, Nagasaki University, and Juntendo University. Patients: A cohort of 8 patients with MG with clinically defined inflammatory myopathies. Interventions: Clinical and histological features were described. Serological analyses included MG-related antistriational autoantibodies (those to titin, ryanodine receptor, muscular voltage-gated potassium channel Kv1.4) and myositis-specific autoantibodies. Results: Of 924 patients with MG, 8 (0.9%) had inflammatory myopathies. The mean (SD) onset age ofMGwas 55.3(10.3) years. All patients showed severe symptoms with bulbar involvement; 5 patients had myasthenic crisis and 4 had invasive thymoma. Myocarditis was found in 3 patients and myositis in 6. Myocarditis, developing 13 to 211 months after the MG onset, was characterized by heart failure and arrhythmias. Myositis, developing before or at the same time as MG, affected limb and paraspinal muscles. Histological findings of skeletal muscles showed CD8+ lymphocyte infiltration. Seven patients had 1 of these antistriational autoantibodies but not myositis-specific autoantibodies. Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died. Conclusions: Heart and skeletal muscles are autoimmune targets in some patients with MG. This autoimmunity has a broad clinical spectrum with antistriational autoantibodies.

UR - http://www.scopus.com/inward/record.url?scp=70449650324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449650324&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2009.229

DO - 10.1001/archneurol.2009.229

M3 - Article

VL - 66

SP - 1334

EP - 1338

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -